Psychotropic-Induced Hyperprolactinemia: A Clinical Review

Psychosomatics

Volumn 55, Issue 1, 2014, Pages 29-36

  Ajmal, Adnan ^a   Joffe, Hadine ^a   Nachtigall, Lisa B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ARIPIPRAZOLE; BUTYROPHENONE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PHENOTHIAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; VENLAFAXINE; ZIPRASIDONE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

AMENORRHEA; BONE DENSITY; CANCER RISK; DISEASE SEVERITY; ERECTILE DYSFUNCTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMENORRHEA; OSTEOLYSIS; PROLACTIN BLOOD LEVEL; PROSTATE CANCER; REVIEW; SEXUAL DYSFUNCTION; CHEMICALLY INDUCED; FEMALE; MALE; PATHOPHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE;

EID: 84891366083     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2013.08.008     Document Type: Review

References (43)

1. Inder W.J., Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 2011, 45:830-837.
2. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol 2010, 25:281-297.
3. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003, 28(1 Suppl):53-67.
4. Montgomery J., Winterbottom E., Jessani M., et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004, 65:1491-1498.
5. Milano W., D'Acunto C.W., De Rosa M., et al. Recent clinical aspects of hyperprolactinemia induced by antipsychotics. Rev Recent Clin Trials 2011, 6:52-63.
6. Wieck A., Haddad P. Hyperprolactinaemia caused by antipsychotic drugs. Br Med J 2002, 324:250-252.
7. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
8. Foley K.F., Kast R.E. Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate. Gen Hosp Psychiatry 2006, 28:230-233.
9. Torre D.L., Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007, 3:929-951.
10. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J Clin Psychiatry 2005, 66:761-767.
11. Potkin S.G. Asenapine: a clinical overview. J Clin Psychiatry 2011, 72(1 Suppl):14-18.
12. Citrome L., Cucchiaro J., Sarma K., et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012, 27:165-176.
13. Schoemaker J., Naber D., Vrijland P., Panagides J., Emsley R. Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010, 43:138-146.
14. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002, 47:27-38.
15. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005, 162:1984-1985.
16. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000, 57:553-559.
17. Arakawa R., Okumura M., Ito H., et al. Positron emission tomography measurement of dopamine D(2) receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 2010, 71:1131-1137.
18. Bressan R.A., Erlandsson K., Spencer E.P., Ell P.J., Pilowsky L.S. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004, 175:367-373.
19. Kuhn K.U., Meyer K., Maier W. Flupenthixol-a partial atypical neuroleptic?. Fortschr Neurol Psychiatr 2000, 68(1 Suppl):S38-S41.
20. Schlosser R., Grunder G., Anghelescu I., et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002, 46:33-40.
21. Coker F., Taylor D. Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management. CNS Drugs 2010, 24:563-574.
22. Papakostas G.I., Miller K.K., Petersen T., et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry 2006, 67:952-957.
23. Serretti A., Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011, 26:130-140.
24. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008, 23:201-209.
25. Kennedy S.H., Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009, 29:157-164.
26. Cardozo L., Bachmann G., McClish D., Fonda D., Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998, 92(4 Pt 2):722-727.
27. Wu R.R., Jin H., Gao K., et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012, 169:813-821.
28. Kishimoto T., De Hert M., Carlson H.E., Manu P., Correll C.U. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012, 25:415-429.
29. Biller B.M., Baum H.B., Rosenthal D.I., Saxe V.C., Charpie P.M., Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992, 75:692-697.
30. Klibanski A., Biller B.M., Rosenthal D.I., Schoenfeld D.A., Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988, 67:124-130.
31. Naliato E.C., Farias M.L., Braucks G.R., Costa F.S., Zylberberg D., Violante A.H. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 2005, 28:12-17.
32. Kayath M.J., Lengyel A.M., Vieira J.G. Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 1993, 26:933-941.
33. Bushe C.J., Bradley A., Pendlebury J. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?. Ann Clin Biochem 2010, 47(Pt 4):292-300.
34. Berinder K., Akre O., Granath F., Hulting A.L. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011, 165:209-215.
35. Melmed S., Casanueva F.F., Hoffman A.R., et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:273-288.
36. Kearns A.E., Goff D.C., Hayden D.L., Daniels G.H. Risperidone-associated hyperprolactinemia. Endocr Pract 2000, 6:425-429.
37. Meltzer H.Y., Fang V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976, 33:279-286.
38. Lu M.L., Shen W.W., Chen C.H. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1978-1981.
39. Casey D.E., Carson W.H., Saha A.R., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003, 166:391-399.
40. Shim J.C., Shin J.G., Kelly D.L., et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007, 164:1404-1410.
41. Kane J.M., Correll C.U., Goff D.C., et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009, 70:1348-1357.
42. Yasui-Furukori N., Furukori H., Sugawara N., Fujii A., Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010, 30:596-599.
43. Lee M.S., Song H.C., An H., et al. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci 2010, 64:19-27.